.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,858,650

« Back to Dashboard
Patent 6,858,650 protects TOVIAZ and is included in one NDA. There has been one Paragraph IV challenge on Toviaz. There are ten tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has sixty-seven patent family members in twenty-nine countries.

Summary for Patent: 6,858,650

Title: Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s): Meese; Claus (Monheim, DE)
Assignee: Schwarz Pharma AG (DE)
Application Number:10/130,214
Patent Claim Types:
see list of patent claims
Compound; Formulation; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 7th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-001Oct 31, 2008RXNo6,858,650► subscribeY TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008RXYes6,858,650► subscribeY TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,858,650

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 55 190Nov 16, 1999
PCT Information
PCT FiledNovember 15, 2000PCT Application Number:PCT/EP00/11309
PCT Publication Date:May 25, 2001PCT Publication Number: WO01/35957

International Patent Family for Patent: 6,858,650

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1230209► subscribe
Poland201422► subscribe
Poland356766► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc